NCT07358533Not yet recruiting
Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud
Disorders Hidden Under the Guise of BMI - Metabolic Obesity in People With Normal Body Weight (MONW) - the Search for Diagnostic Markers and Its Consequences for Health
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
Metabolically Obese Normal Weight (MONW) represents a phenotype affecting individuals with a normal Body Mass Index (BMI) but characterized by excessive adipose tissue accumulation. This condition is associated with increased cardiovascular risk, insulin resistance, and endothelial dysfunction, yet remains underdiagnosed. This observational longitudinal study aims to comprehensively evaluate the relationship between excessive adipose tissue deposition, endothelial dysfunction, and asprosin concentrations in young women. The study will recruit 176 healthy women aged 18-35 years with normal BMI (\<25 kg/m²). Participants will be divided into two groups based on body fat percentage (PBF) assessed by dual-energy X-ray absorptiometry (DXA): the MONW group (PBF ≥ 35.78%) and the Control group (PBF \< 35.78%). The specific objectives of the study include: * Assessment of vascular endothelial function using flow-mediated dilation (FMD) of the brachial artery. * Evaluation of asprosin as a novel biomarker in the MONW phenotype. * Analysis of biochemical indices including asymmetric dimethylarginine (ADMA) and von Willebrand factor (vWF). * Advanced metabolomic profiling to identify metabolic signatures. Participants will undergo anthropometric measurements, body composition analysis (DXA), and blood sampling for biochemical and hormonal analyses. The study aims to develop predictive models for early cardiovascular risk detection in normal-weight individuals.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 176 (estimated)
- First submitted
- 14 Jan 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- Pomeranian Medical University Szczecin
- Diseases
- Obesity
- NCT number
- NCT07358533
What you commit to
- Study type: Observational
- Planned participants: 176
- From 1 Sept 2026 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hormone therapy and/or use of hormonal contraceptives.
- Metal or silicone implants (contraindication for DXA/body composition accuracy).
- Use of hypolipemic, antihypertensive, antiglycemic, or insulin medications.
Other illness
- Thyroid disease.
- Eating disorders.
- Polycystic ovary syndrome (PCOS).
- Acute and/or chronic illnesses.
- Type I or II diabetes, dyslipidemia, hypertension.
Other
- Pregnancy or breastfeeding.
- Smoking.
- Vitamin and/or mineral supplementation.
Who the study is looking for
- Written, informed consent to participate in the research.
- Gender: Female.
- Age 18-35 years.
- BMI in the range of 18.5-25 kg/m².
Age in the registry: 18 years to 35 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pomeranian Medical University in Szczecin Coordinator of this site? Confirm its status | Szczecin | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.